NORCEPT-E 1/35 21 Drug Patent Profile
✉ Email this page to a colleague
When do Norcept-e 1/35 21 patents expire, and what generic alternatives are available?
Norcept-e 1/35 21 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.
The generic ingredient in NORCEPT-E 1/35 21 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for NORCEPT-E 1/35 21
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Patent Applications: | 131 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NORCEPT-E 1/35 21 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NORCEPT-E 1/35 21
US Patents and Regulatory Information for NORCEPT-E 1/35 21
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ortho Mcneil Pharm | NORCEPT-E 1/35 21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 071545-001 | Feb 9, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |